Natalizumab (Tysabry®) is a humanised monoclonal antibodies (MAb) which blocks alpha4beta1 integrin-mediated leukocyte migration; it is one among the plethora of pharmacological treatments against multiple sclerosis (MS) [1,2]. Some reports describe a relationship between clinical syndromes and administration of Mab, in particular on thyroid gland [3,4]. Therefore, only few data have been so far reported about cardiac involvement and MAb-therapy. We report here an unusual case of acute myocardial damage likely induced by taking Natalizumab, in an young woman in treatment for a relapsing–remitting (RR) MS.

Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?

Cicciu', Marco;
2016-01-01

Abstract

Natalizumab (Tysabry®) is a humanised monoclonal antibodies (MAb) which blocks alpha4beta1 integrin-mediated leukocyte migration; it is one among the plethora of pharmacological treatments against multiple sclerosis (MS) [1,2]. Some reports describe a relationship between clinical syndromes and administration of Mab, in particular on thyroid gland [3,4]. Therefore, only few data have been so far reported about cardiac involvement and MAb-therapy. We report here an unusual case of acute myocardial damage likely induced by taking Natalizumab, in an young woman in treatment for a relapsing–remitting (RR) MS.
2016
Natalizumab
Toxic acute myocardial damage
Multiple sclerosis
Monoclonal antibodies
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/553790
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact